



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 51**

(48) Corrigendum issued on:  
**01.06.2016 Bulletin 2016/22**

(45) Date of publication and mention  
of the grant of the patent:  
**29.05.2013 Bulletin 2013/22**

(21) Application number: **08725256.5**

(22) Date of filing: **07.02.2008**

(51) Int Cl.:  
**A61K 31/225** <sup>(2006.01)</sup> **A61K 31/137** <sup>(2006.01)</sup>  
**A61K 31/194** <sup>(2006.01)</sup> **A61K 31/197** <sup>(2006.01)</sup>  
**A61K 31/277** <sup>(2006.01)</sup> **A61K 31/436** <sup>(2006.01)</sup>  
**A61K 31/4704** <sup>(2006.01)</sup> **A61K 31/7076** <sup>(2006.01)</sup>  
**A61K 38/21** <sup>(2006.01)</sup> **A61K 45/06** <sup>(2006.01)</sup>  
**G01N 33/50** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2008/001602**

(87) International publication number:  
**WO 2008/097596 (14.08.2008 Gazette 2008/33)**

(54) **Compositions and Uses for Treating Multiple Sclerosis**

Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerosis

Compositions et leurs utilisations pour le traitement de la Sclérose en plaques

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT**  
**RO SE SI SK TR**  
Designated Extension States:  
**AL BA MK RS**

(30) Priority: **08.02.2007 US 888921 P**

(43) Date of publication of application:  
**30.12.2009 Bulletin 2009/53**

(60) Divisional application:  
**12169644.7 / 2 518 511**  
**13156663.0 / 2 629 097**  
**13169139.6 / 2 653 873**  
**13179016.4 / 2 680 006**  
**13179021.4 / 2 680 007**  
**13179023.0 / 2 680 008**  
**13179024.8 / 2 680 009**  
**13179025.5 / 2 680 010**

(73) Proprietor: **Biogen MA Inc.**  
**Cambridge, MA 02142 (US)**

(72) Inventors:  
• **LUKASHEV, Matvey, E.**  
**Tewksbury, MA 01876 (US)**  
• **O'NEILL, Gilmore**  
**Medford, MA 02155 (US)**

(74) Representative: **Pohlman, Sandra M.**  
**df-mp Dörries Frank-Molnia & Pohlman**  
**Patentanwälte Rechtsanwälte PartG mbB**  
**Theatinerstrasse 16**  
**80333 München (DE)**

(56) References cited:  
**WO-A-2007/005879 WO-A2-2006/037342**  
• **SCHIMRIGK S ET AL: "Oral fumaric acid esters  
for the treatment of active multiple sclerosis: an  
open-label, baseline-controlled pilot study"**  
**EUROPEAN JOURNAL OF NEUROLOGY, vol. 13,**  
**no. 6, June 2006 (2006-06), pages 604-610,**  
**XP002496537 ISSN: 1351-5101**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- WIERINCKX ET AL: "Detoxication enzyme inducers modify cytokine production in rat mixed glial cells" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 166, no. 1-2, 1 September 2005 (2005-09-01), pages 132-143, XP005000427 ISSN: 0165-5728
- GOLD R ET AL: "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, vol. 253, no. Suppl. 2, 1 May 2006 (2006-05-01), pages II144-II145, XP009157336, ISSN: 0340-5354

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification